Form 4 for COGT Cogent Biosciences, Inc.
Accepted 2026-08-31 17:01:57 ET · period of report 2026-08-27 · accession 0001193125-26-377001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-31 17:01 | 2026-08-27 | COGT | Morris Arlene | Dir | M - OptEx | $5.39 | +45.5K | 45.5K | New | +$245.5K |
| DMT | 2026-08-31 17:01 | 2026-08-27 | COGT | Morris Arlene | Dir | S - Sale+OE | $37.12 | -45.5K | 0 | -100% | -$1.69M |
| DMT | 2026-08-31 17:01 | 2026-08-27 | COGT | Morris Arlene | Dir | M - OptEx | $0.00 | -45.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-27 | M | A | 41,927 | $5.64 | 41,927 | D | — | — | (F1) Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. |
| 2 | Common | Common Stock | 2026-08-27 | M | A | 3,583 | $2.52 | 45,510 | D | — | — | (F1) Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. |
| 3 | Common | Common Stock | 2026-08-27 | S | D | 42,349 | $37.09 | 3,161 | D | — | — | (F1) Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2026-08-27 | S | D | 3,161 | $37.54 | 0 | D | — | — | (F1) Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-08-27 | M | D | 41,927 | $0.00 | 2,773 | D | $5.64 · — to 2035-06-04 | 41,927 Common Stock | (F1) Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. (F4) These options are fully vested. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-08-27 | M | D | 3,583 | $0.00 | 0 | D | $2.52 · — to 2030-06-09 | 3,583 Common Stock | (F1) Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. (F4) These options are fully vested. |